Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wei Zhao
• Collaborator: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Treatments: Anti-Infective Agents; Antineoplastic Agents; Asparaginase; Bortezomib; Dasatinib; Imatinib Mesylate; Lenograstim; Pegaspargase; Sargramostim

Criteria

Inclusion Criteria:

• Patients must be diagnosed with hematological neoplasms

• Antineoplastic drugs or anti-infective drugs used as part of regular treatment

Exclusion Criteria:

• expected survival time less than the treatment cycle;

• patients with other factors that researcher considers unsuitable for inclusion.